Blade Air Mobility (BLDE)

• Market cap: $332M
• 1 day: -3.85%
• 5 days: 7.89%
• 1 month: -4.93%
• 3 months: 44.22%
• 6 months: 27.33%
• Year to date: 24.34%
• 1 year: 24.34%
• 5 years: -45.08%
• 10 years: -45.08%
• Sector: Industrials
• Industry: Air Transportation, Nonscheduled

About: Blade Air Mobility Inc is a technology-powered air mobility platform that provides air transportation and logistics for hospitals and is a transporter of human organs for transplant, and for passengers, with helicopter and fixed-wing services predominantly in the Northeast United States, Southern Europe and Western Canada. The company's operating segments are; Passenger, and Medical. Majority of the revenue for the company is generated from its Medical segment which predominantly consists of transportation of human organs for transplant and the medical teams supporting these services. It also offers additional services including donor logistics coordination and support in evaluating potential donor organs. A substantial portion of the company's revenue is generated from the United States.

Employees: 281

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

288% more call options, than puts

Call options by funds: $303K | Put options by funds: $78K

32% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 31

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

3% more funds holding

Funds holding: 116 [Q2] → 119 (+3) [Q3]

2.0% more ownership

Funds ownership: 51.76% [Q2] → 53.76% (+2.0%) [Q3]

11% less capital invested

Capital invested by funds: $139M [Q2] → $123M (-$15.9M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6 42% upside
• Avg. target: $6 42% upside
• High target: $6 42% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Bill Peterson 38% 1-year accuracy 10 / 26 met price target

42% upside $6

Overweight Maintained

29 Oct 2024